27 research outputs found
Barriers to routine G6PD testing prior to treatment with primaquine
Background
Primaquine is essential for the radical cure of vivax malaria, however its broad application is hindered
by the risk of drug-induced haemolysis in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency.
Rapid diagnostic tests capable of diagnosing G6PD deficiency are now available, but these are not used widely.
Methods
A series of qualitative interviews were conducted with policy makers and healthcare providers in four
vivax-endemic countries. Routine G6PD testing is not part of current policy in Bangladesh, Cambodia or China, but
it is in Malaysia. The interviews were analysed with regard to respondents perceptions of vivax malaria, -primaquine
based treatment for malaria and the complexities of G6PD deficiency.
Results
Three barriers to the roll-out of routine G6PD testing were identified in all sites: (a) a perceived low risk
of drug-induced haemolysis; (b) the perception that vivax malaria was benign and accordingly treatment with
primaquine was not regarded as a priority; and, (c) the additional costs of introducing routine testing. In Malaysia,
respondents considered the current test and treat algorithm suitable and the need for an alternative approach was
only considered relevant in highly mobile and hard to reach populations.
Conclusions
Greater efforts are needed to increase awareness of the benefits of the radical cure of Plasmodium vivax
and this should be supported by economic analyses exploring the cost effectiveness of routine G6PD testing.</p
Socializing One Health: an innovative strategy to investigate social and behavioral risks of emerging viral threats
In an effort to strengthen global capacity to prevent, detect, and control infectious diseases in animals and people, the United States Agency for International Development’s (USAID) Emerging Pandemic Threats (EPT) PREDICT project funded development of regional, national, and local One Health capacities for early disease detection, rapid response, disease control, and risk reduction. From the outset, the EPT approach was inclusive of social science research methods designed to understand the contexts and behaviors of communities living and working at human-animal-environment interfaces considered high-risk for virus emergence. Using qualitative and quantitative approaches, PREDICT behavioral research aimed to identify and assess a range of socio-cultural behaviors that could be influential in zoonotic disease emergence, amplification, and transmission. This broad approach to behavioral risk characterization enabled us to identify and characterize human activities that could be linked to the transmission dynamics of new and emerging viruses. This paper provides a discussion of implementation of a social science approach within a zoonotic surveillance framework. We conducted in-depth ethnographic interviews and focus groups to better understand the individual- and community-level knowledge, attitudes, and practices that potentially put participants at risk for zoonotic disease transmission from the animals they live and work with, across 6 interface domains. When we asked highly-exposed individuals (ie. bushmeat hunters, wildlife or guano farmers) about the risk they perceived in their occupational activities, most did not perceive it to be risky, whether because it was normalized by years (or generations) of doing such an activity, or due to lack of information about potential risks. Integrating the social sciences allows investigations of the specific human activities that are hypothesized to drive disease emergence, amplification, and transmission, in order to better substantiate behavioral disease drivers, along with the social dimensions of infection and transmission dynamics. Understanding these dynamics is critical to achieving health security--the protection from threats to health-- which requires investments in both collective and individual health security. Involving behavioral sciences into zoonotic disease surveillance allowed us to push toward fuller community integration and engagement and toward dialogue and implementation of recommendations for disease prevention and improved health security
Strengthening quit smoking services in Malaysia through Malaysia Quit (mQuit) Program
Background and challenges to implementation
Base on the Malaysian National Health Morbidity Survey in 2011, 48.6% of smokers have made quit attempt in the past 12 months but only 32.4% visited health care provider (HCP). One of the main challenges of getting professional advice in quitting is due to limited cessation services within public clinics and hospital. To overcome this and in line with Article 14 WHO Framework Convention on Tobacco Control (FCTC), Malaysia has developed a holistic and structured program under Malaysia Quit or mQuit services.
Intervention or response
The mQuit services
was inaugurated on 27 th November 2015 through public-private
partnership with the objective to make smoking cessation services accessible
throughout the public and private sectors. The services were further enhanced
with a quitline counselling system and a website to promote and facilitate
registration of smokers to cessation program through www.jomquit.moh.gov.my. Both
mQuit providers in public and private sectors have to fulfil standard criteria
set by the Ministry of Health before accreditation given and the list is made available
in the jomquit website. To date, 160 private HCP and 764 government health clinics and hospitals have become mQuit
providers.
Results and lessons learnt
The number of registered patients have increased from 7757
in 2015 to 10791 in 2016. Since services start in private sector, the total
number registered with private mQuit providers has increased from 10 patients
in January 2017 to total of 394 patients until June 2017. The total number of registration through
jomquit website was 420 patients. The implementation of the mQuit encountered a
few challenges at first. Challenges and recommendations are discussed with all
partners and remedial measures were applied to improve the services.
Conclusions and key recommendations
The mQuit services has increased accessibility to
smoking cessation services in Malaysia
The challenges of introducing routine G6PD testing into radical cure: a workshop report
The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recommended routine testing of G6PD status prior to primaquine radical cure whenever possible. A workshop was held in the Philippines in early 2015 to discuss key challenges and knowledge gaps that hinder the introduction of routine G6PD testing. Two point-of-care (PoC) test formats for the measurement of G6PD activity are currently available: qualitative tests comparable to malaria RDT as well as biosensors that provide a quantitative reading. Qualitative G6PD PoC tests provide a binomial test result, are easy to use and some products are comparable in price to the widely used fluorescent spot test. Qualitative test results can accurately classify hemizygous males, heterozygous females, but may misclassify females with intermediate G6PD activity. Biosensors provide a more complex quantitative readout and are better suited to identify heterozygous females. While associated with higher costs per sample tested biosensors have the potential for broader use in other scenarios where knowledge of G6PD activity is relevant as well. The introduction of routine G6PD testing is associated with additional costs on top of routine treatment that will vary by setting and will need to be assessed prior to test introduction. Reliable G6PD PoC tests have the potential to play an essential role in future malaria elimination programmes, however require an improved understanding on how to best integrate routine G6PD testing into different health settings
Southeast Asia Strategic Multilateral Dialogue on Biosecurity
A strategic multilateral dialogue related to biosecurity risks in Southeast Asia, established in 2014, now includes participants from Singapore, Malaysia, Indonesia, Thailand, Philippines, and the United States. This dialogue is conducted at the nonministerial level, enabling participants to engage without the constraints of operating in their official capacities. Participants reflect on mechanisms to detect, mitigate, and respond to biosecurity risks and highlight biosecurity issues for national leadership. Participants have also identified factors to improve regional and global biosecurity, including improved engagement and collaboration across relevant ministries and agencies, sustainable funding for biosecurity programs, enhanced information sharing for communicable diseases, and increased engagement in international biosecurity forums
Barriers to routine G6PD testing prior to treatment with primaquine
Abstract Background Primaquine is essential for the radical cure of vivax malaria, however its broad application is hindered by the risk of drug-induced haemolysis in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. Rapid diagnostic tests capable of diagnosing G6PD deficiency are now available, but these are not used widely. Methods A series of qualitative interviews were conducted with policy makers and healthcare providers in four vivax-endemic countries. Routine G6PD testing is not part of current policy in Bangladesh, Cambodia or China, but it is in Malaysia. The interviews were analysed with regard to respondents perceptions of vivax malaria, -primaquine based treatment for malaria and the complexities of G6PD deficiency. Results Three barriers to the roll-out of routine G6PD testing were identified in all sites: (a) a perceived low risk of drug-induced haemolysis; (b) the perception that vivax malaria was benign and accordingly treatment with primaquine was not regarded as a priority; and, (c) the additional costs of introducing routine testing. In Malaysia, respondents considered the current test and treat algorithm suitable and the need for an alternative approach was only considered relevant in highly mobile and hard to reach populations. Conclusions Greater efforts are needed to increase awareness of the benefits of the radical cure of Plasmodium vivax and this should be supported by economic analyses exploring the cost effectiveness of routine G6PD testing
COVID-19 in Malaysia:Descriptive Epidemiologic Characteristics of the First Wave
This study aimed to describe the characteristics of COVID-19 cases and close contacts during the first wave of COVID-19 in Malaysia (23 January 2020 to 26 February 2020), and to analyse the reasons why the outbreak did not continue to spread and lessons that can be learnt from this experience. Characteristics of the cases and close contacts, spatial spread, epidemiological link, and timeline of the cases were examined. An extended SEIR model was developed using several parameters such as the average number of contacts per day per case, the proportion of close contact traced per day and the mean daily rate at which infectious cases are isolated to determine the basic reproduction number (R0) and trajectory of cases. During the first wave, a total of 22 cases with 368 close contacts were traced, identified, tested, quarantine and isolated. Due to the effective and robust outbreak control measures put in place such as early case detection, active screening, extensive contact tracing, testing and prompt isolation/quarantine, the outbreak was successfully contained and controlled. The SEIR model estimated the R0 at 0.9 which further supports the decreasing disease dynamics and early termination of the outbreak. As a result, there was a 11-day gap (free of cases) between the first and second wave which indicates that the first wave was not linked to the second wave